Actuate Therapeutics will present at the H.C. Wainwright 28th Annual Global Investment Conference in New York City on September 14, 2026, at 4:00 p.m. ET. Management will also be available for one-on-one meetings during the September 14-16 conference, with a webcast accessible through the company’s Investor section. Actuate is developing therapies for high-impact, difficult-to-treat cancers. Its lead investigational drug, elraglusib, is a novel GSK-3β inhibitor designed to target molecular pathways associated with tumor growth and resistance to conventional cancer drugs such as chemotherapy by inhibiting NF-κB and DNA Damage Response pathways. The company says elraglusib may also influence anti-tumor immunity through multiple immune checkpoints and immune-cell function.